Last quarter (Q ), Aeolus Pharmaceuticals's total revenue was $13.00K, a decrease of -98.03% from the same quarter last year. In Q, Aeolus Pharmaceuticals's net income was $-949.00K. See Aeolus Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 16	Sep 15	Sep 14	Sep 13	Sep 12
Total Revenue	$ 771.00K	$ 2.08M	$ 3.11M	$ 9.63M	$ 3.93M	$ 7.29M
Cost of Revenue	-	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	-	-	$ 3.11M	$ 9.63M	$ 3.93M	$ 7.29M
Operating Expense	$ 4.87M	$ 5.35M	$ 5.74M	$ 9.71M	$ 6.63M	$ 9.66M
Operating Income	$ -4.09M	$ -3.27M	$ -2.63M	$ -80.00K	$ -2.70M	$ -2.37M
Net Non Operating Interest Income Expense	-	$ -285.00K	$ -2.00K	$ 0.00	-	$ 0.00
Other Income Expense	-	-	-	-	$ -510.00K	$ 4.07M
Pretax Income	$ -4.09M	$ -3.56M	$ -2.63M	$ -80.00K	$ -3.21M	$ 1.70M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -4.09M	$ -6.04M	$ -2.63M	$ -80.00K	$ -3.21M	$ 856.00K
Basic EPS	$ -0.04	$ -0.04	$ -0.02	$ 0.00	$ -0.03	$ 0.03
Diluted EPS	$ -0.04	$ -0.04	$ -0.02	$ 0.00	$ -0.03	$ 0.02
Basic Average Shares	$ 608.37M	$ 148.67M	$ 135.88M	$ 134.67M	$ 106.55M	$ 61.59M
Diluted Average Shares	$ 608.37M	$ 148.67M	$ 135.88M	$ 134.67M	$ 106.55M	$ 72.75M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 4.87M	$ 5.35M	$ 5.74M	$ 9.71M	$ 6.63M	$ 9.66M
Net Income From Continuing And Discontinued Operation	$ -4.09M	$ -3.56M	$ -2.63M	$ -80.00K	$ -3.21M	$ 1.70M
Normalized Income	$ -4.09M	$ -3.56M	$ -2.63M	$ -80.00K	$ -2.70M	$ -946.85K
Interest Expense	-	$ 285.00K	$ 2.00K	$ 0.00	-	$ 0.00
EBIT	$ -4.09M	$ -3.27M	$ -2.63M	$ -80.00K	$ -2.70M	$ -2.37M
EBITDA	$ -4.09M	$ -3.27M	$ -2.63M	$ -80.00K	$ -2.69M	$ -2.36M

Currency in USD

Aeolus Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing